BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1296011)

  • 1. Community attributable risk: its economic dimensions.
    Wilhelmsen L
    J Hum Hypertens; 1992 Dec; 6(6):469-72. PubMed ID: 1296011
    [No Abstract]   [Full Text] [Related]  

  • 2. Costs and benefits of community programmes for the control of hypertension.
    Nissinen A; Tuomilehto J; Enlund H; Kottke TE
    J Hum Hypertens; 1992 Dec; 6(6):473-9. PubMed ID: 1296012
    [No Abstract]   [Full Text] [Related]  

  • 3. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies].
    Rorive G; Delporte JP
    Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderately elevated blood pressure. A report from SBU, the Swedish Council on Technology Assessment in Health Care.
    J Intern Med Suppl; 1995; 737():1-225. PubMed ID: 9043531
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypertension, a health economics perspective.
    Alcocer L; Cueto L
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):147-55. PubMed ID: 19124418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing the economic value of antihypertensive medications.
    Roth MS; Davenport RC; Simpson W
    Am J Manag Care; 1998 Sep; 4(9):1267-75. PubMed ID: 10185977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medical economics of antihypertensive agents].
    Yamazaki T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():285-8. PubMed ID: 16981557
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blockers: impact on costs of care.
    Am J Manag Care; 2005 Nov; 11(13 Suppl):S400-3. PubMed ID: 16300456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fully possible to reduce the costs of hypertension treatment].
    Wettermark B; Angman A; Hjemdahl P
    Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
    [No Abstract]   [Full Text] [Related]  

  • 12. Economics of hypertension control. World Hypertension League.
    Bull World Health Organ; 1995; 73(4):417-24. PubMed ID: 7554012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.
    Johannesson M
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economic issues and the future treatment and management of hypertension.
    Giles TD
    AAPPO J; 1994; 4(4):27-8, 30, 33-5. PubMed ID: 10150589
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda.
    Okello D; Floyd K; Adatu F; Odeke R; Gargioni G
    Int J Tuberc Lung Dis; 2003 Sep; 7(9 Suppl 1):S72-9. PubMed ID: 12971657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness.
    Tuulonen A; Azuara-Blanco A
    Ophthalmology; 2009 Jan; 116(1):166-7; author reply 167. PubMed ID: 19118707
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness.
    Brown GC; Brown MM
    Ophthalmology; 2008 Aug; 115(8):1433; author reply 1433-4. PubMed ID: 18675701
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi.
    Floyd K; Skeva J; Nyirenda T; Gausi F; Salaniponi F
    Int J Tuberc Lung Dis; 2003 Sep; 7(9 Suppl 1):S29-37. PubMed ID: 12971652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness.
    Lichter PR
    Ophthalmology; 2008 Oct; 115(10):1852-3; author reply 1853. PubMed ID: 18929170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.